

Applicant/PHCR: AUROBINDO PHARMA (PTY) LTD
Product proprietary name: ETAMEP
Dosage form and strength: LYOPHILISED POWDER FOR SOLUTION FOR INJECTION

SCHEDULING STATUS:

S4

PROPRIETARY NAME (and dosage form):

ETAMEP (lyophilised powder for solution for injection)

COMPOSITION:

ETAMEP: Each vial contains 1 g ertapenem.

The other ingredient of **ETAMEP** is sodium bicarbonate.

PHARMACOLOGICAL CLASSIFICATION:

A 20.1.1 Broad and medium spectrum antibiotics

PHARMACOLOGICAL ACTION:

Pharmacological properties

Ertapenem is a sterile, synthetic, long acting, parenteral, 1- β methyl-carbapenem that is structurally related to beta-lactam antibiotics, such as penicillins and cephalosporins, with activity against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria.

The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In *Escherichia coli*, it has strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preference for PBPs 2 and 3. Ertapenem has significant stability to hydrolysis by most classes of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases, but not metallo-beta-lactamases.

Resistant organisms

Corynebacterium spp., *Enterococcus* spp. (including *Enterococcus faecalis* and *Enterococcus faecium*), methicillin resistant *Staphylococcus aureus*, methicillin resistant coagulase negative *Staphylococcus*, *Acinetobacter* spp., *Pseudomonas* spp., *Stenotrophomonas maltophilia*.

Pharmacokinetic properties

ETAMEP
(*Ertapenem 1 g/Vial, Lyophilised Powder for Solution for Injection*)

Absorption

Ertapenem, reconstituted with 1 % lidocaine (lignocaine) hydrochloride injection, USP (in saline without epinephrine (adrenaline)), is well absorbed following IM administration at the recommended dose of 1 g. The mean bioavailability is approximately 92 %. Following 1 g daily IM administration, mean peak plasma concentrations (C_{max}) are reached in approximately 2 hours (T_{max}).

Distribution

Ertapenem is highly bound to human plasma proteins. In healthy young adults, the protein binding of ertapenem decreases as plasma concentrations increase, from approximately 95 % bound at an approximate plasma concentration of less than 100 $\mu\text{g/mL}$ to approximately 85 % bound at an approximate plasma concentration of 300 $\mu\text{g/mL}$.

Average plasma concentrations ($\mu\text{g/mL}$) of ertapenem following a single 30-minute IV infusion of a 1 or 2 g dose and IM administration of a single 1 g dose in healthy young adults showed that the area under the plasma concentration curve (AUC) of ertapenem in adults increases nearly dose-proportionally over the 0,5 to 2 g dose range.

There is no accumulation of ertapenem in adults following multiple IV doses ranging from 0,5 to 2 g daily or IM doses of 1 g daily.

Average plasma concentrations ($\mu\text{g/mL}$) of ertapenem in paediatric patients showed that the volume of distribution (V_{dss}) of ertapenem in adults is approximately 8 litres (0,11 litre/kg) and approximately 0,2 litre/kg in paediatric patients 3 months to 12 years of age and approximately 0,16 litre/kg in paediatric patients 13 to 17 years of age.

Ertapenem penetrates into suction-induced skin blisters. The ratio of AUC in skin blister fluid to AUC in plasma is 0,61.

The level of ertapenem in breast milk of 5 lactating women was measured at random time points daily for 5 consecutive days following the last 1 g dose of intravenous therapy. The measured concentration of ertapenem in breast milk on the last day of therapy (5 to 14 days postpartum) in all 5 women was less than 0,38 $\mu\text{g/mL}$; peak concentrations were not assessed. By day 5 after discontinuation of therapy, the level of ertapenem was undetectable in the breast milk of 4 women and was detected at trace levels (less than 0,13 $\mu\text{g/mL}$) in one woman.

In vitro studies indicate that ertapenem does not inhibit P-glycoprotein-mediated transport of digoxin or vinblastine and that ertapenem is not a substrate for P-glycoprotein-mediated transport (see **INTERACTIONS**).

Metabolism

In healthy young adults, after IV infusion of radio labelled 1 g ertapenem, the plasma radioactivity consists predominantly (94 %) of ertapenem. The major metabolite of ertapenem is the ring-opened derivative formed by hydrolysis of the beta-lactam ring.

In vitro studies in human liver microsomes indicate that ertapenem does not inhibit metabolism mediated by any of the six major cytochrome P450 (CYP) isoforms: 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4.

Elimination

Ertapenem is eliminated primarily by the kidneys. The mean plasma half-life in healthy young adults and patients 13 to 17 years of age is approximately 4 hours and approximately 2,5 hours in paediatric patients 3 months to 12 years of age.

Following administration of a 1 g radio labelled IV dose of ertapenem to healthy young adults, approximately 80 % is recovered in urine and 10 % in faeces. Of the 80 % recovered in urine, approximately 38 % is excreted as unchanged drug and approximately 37 % as the ring-opened metabolite.

In healthy young adults given a 1 g IV dose, average concentrations of ertapenem in urine exceed 984 µg/mL during the period 0 to 2 hours post dose and exceed 52 µg/mL during the period 12 to 24 hours post dose.

Special populations

Elderly

Plasma concentrations following a 1 g and 2 g IV dose of ertapenem are slightly higher (approximately 39 % and 22 % respectively) in elderly adults (65 years or older) relative to young adults (younger than 65 years). No dosage adjustment is necessary in elderly patients.

Paediatric patients

Plasma concentrations of ertapenem are comparable in paediatric patients 13 to 17 years of age and adults following a 1 g once daily IV dose.

Following the 20 mg/kg dose (up to a maximum dose of 1 g), the pharmacokinetic parameter values in patients 13 to 17 years of age were generally comparable to those in healthy young adults.

Plasma concentrations at the midpoint of the dosing interval following a single 15 mg/kg IV dose of ertapenem in patients 3 months to 12 years of age are comparable to plasma concentrations at the midpoint of the dosing interval following a 1 g once daily IV dose in adults (see **Distribution**).

Hepatic insufficiency

The pharmacokinetics of ertapenem in patients with hepatic insufficiency have not been established. Due to the limited extent of hepatic metabolism of ertapenem, its pharmacokinetics are not expected to be affected by hepatic impairment. Therefore, no dosage adjustment is necessary in patients with hepatic impairment.

Renal insufficiency

Following a single 1 g IV dose of ertapenem in adults, AUC is similar in patients with mild renal insufficiency (Cl_{cr} 60 to 90 mL/min/1,73 m²) compared with healthy subjects (ages 25 to 82 years). AUC is increased in patients with moderate renal insufficiency (Cl_{cr} 31 to 59 mL/min/1,73 m²) approximately 1,5 fold compared with healthy subjects. AUC is increased in patients with advanced renal insufficiency (Cl_{cr} 5 to 30 mL/min/1,73 m²) approximately 2,6 fold compared with healthy subjects. AUC is increased in patients with end stage renal insufficiency (Cl_{cr} less than 10 mL/min/1,73 m²) approximately 2,9 fold compared with healthy subjects. Following a single 1 g IV dose given immediately prior to a haemodialysis session, approximately 30 % of the dose is recovered in the dialysate. There are no data in paediatric patients with renal insufficiency.

A dosage adjustment is recommended for patients with advanced or end-stage renal insufficiency (see **DOSAGE AND DIRECTIONS FOR USE**).

INDICATIONS:

ETAMEP is indicated for the treatment of adult patients with the following moderate to severe infections caused by susceptible strains of the designated micro-organisms (see **DOSAGE AND DIRECTIONS FOR USE**):

Complicated intra-abdominal infections due to *Escherichia coli*, *Clostridium clostridioforme*, *Eubacterium lentum*, *Peptostreptococcus* species, *Bacteroides fragilis*, *Bacteroides distasonis*, *Bacteroides ovatus*, *Bacteroides thetaiotaomicron*, or *Bacteroides uniformis*.

Complicated skin and skin structure infections including diabetic lower extremity and diabetic foot infections due to *Staphylococcus aureus* (methicillin susceptible strains only), *Streptococcus agalactiae*, *Streptococcus pyogenes*, *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis*, *Porphyromonas asaccharolytica* or *Peptostreptococcus* species.

Community acquired pneumonia due to *Streptococcus pneumoniae* (penicillin susceptible strains only) including cases with concurrent bacteraemia, *Moraxella catarrhalis*. If community acquired pneumonia is caused by *Haemophilus influenzae*, **ETAMEP** should be used only following confirmation of culture and sensitivity results.

Complicated urinary tract infections including pyelonephritis due to *Escherichia coli*, including cases with concurrent bacteraemia or *Klebsiella pneumoniae*

Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynaecologic infections due to *Streptococcus agalactiae*, *Escherichia coli*, *Bacteroides fragilis*, *Porphyromonas asaccharolytica*, *Peptostreptococcus* species or *Prevotella bivia*.

Paediatric use

Safety and effectiveness of **ETAMEP** in paediatric patients 3 months to 17 years of age are supported by evidence from adequate and well-controlled studies in adults, pharmacokinetic data in paediatric patients, and additional data from comparator-controlled studies in paediatric patients 3 months to 17 years of age with the following infections (see **DOSAGE AND DIRECTIONS FOR USE**).

- *Complicated intra-abdominal infections*
- *Complicated skin and skin structure infections*
- *Community acquired pneumonia*
- *Complicated urinary tract infections*

- *Acute pelvic infections*

Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify the causative organisms and to determine their susceptibility to **ETAMEP**. Therapy with **ETAMEP** may be initiated empirically before results of these tests are known; once results become available, antimicrobial therapy should be adjusted accordingly.

CONTRAINDICATIONS:

ETAMEP is contraindicated in patients with known bacterial meningitis and hypersensitivity to any component of **ETAMEP** or to other medicines in the same class or in patients who have demonstrated anaphylactic reactions to beta-lactams.

ETAMEP, when administered intramuscularly with lidocaine hydrochloride diluent, is contraindicated in patients with a known hypersensitivity to local anaesthetics of the amide type and in patients with severe shock or heart block.

ETAMEP is not recommended in the treatment of meningitis due to lack of sufficient cerebrospinal fluid (CSF) penetration.

WARNINGS AND SPECIAL PRECAUTIONS:

SERIOUS AND OCCASIONALLY FATAL HYPERSENSITIVITY (ANAPHYLACTIC) REACTIONS HAVE BEEN REPORTED IN PATIENTS RECEIVING THERAPY WITH BETA-LACTAMS. THESE REACTIONS ARE MORE LIKELY TO OCCUR IN INDIVIDUALS WITH A HISTORY OF SENSITIVITY TO MULTIPLE ALLERGENS. THERE HAVE BEEN REPORTS OF INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY WHO HAVE EXPERIENCED SEVERE HYPERSENSITIVITY REACTIONS WHEN TREATED WITH ANOTHER BETA-LACTAM. BEFORE INITIATING THERAPY WITH ETAMEP, CAREFUL INQUIRY SHOULD BE MADE CONCERNING PREVIOUS HYPERSENSITIVITY REACTIONS TO PENICILLINS, CEPHALOSPORINS, OTHER BETA-LACTAMS AND OTHER ALLERGENS. IF AN ALLERGIC REACTION TO ETAMEP OCCURS, DISCONTINUE THE ETAMEP IMMEDIATELY. SERIOUS ANAPHYLACTIC REACTIONS REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE/ADRENALINE, OXYGEN,

Applicant/PHCR: AUROBINDO PHARMA (PTY) LTD
Product proprietary name: ETAMEP
Dosage form and strength: LYOPHILISED POWDER FOR SOLUTION FOR INJECTION

INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION. OTHER THERAPY MAY ALSO BE ADMINISTERED AS INDICATED.

Seizures and other central nervous system (CNS) adverse experiences have been reported during treatment with **ETAMEP**.

Pseudomembranous colitis (antibiotic-associated colitis) has been reported with nearly all antibacterial medicines, including ETAMEP, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea subsequent to the administration of antibacterial medicines.

Treatment with antibacterial medicines alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by *Clostridium difficile* is a primary cause of "antibiotic-associated colitis".

After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to **ETAMEP** discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation and treatment with an antibacterial medicine clinically effective against *Clostridium difficile* colitis.

Lidocaine hydrochloride is the diluent for intramuscular administration of **ETAMEP**.

During clinical investigations in adult patients treated with ETAMEP (1 g once a day), seizures, irrespective of medicine relationship, occurred in 0,5 % of patients during study therapy plus 14-day follow-up period. These experiences have occurred most commonly in patients with CNS disorders (e.g. brain lesions or history of seizures) and/or compromised renal function. Close adherence to the recommended dosage regimen is urged, especially in patients with known factors that predispose to convulsive activity. Anticonvulsant therapy should be continued in patients with known seizure disorders. If focal tremors, myoclonus, or seizures occur, patients should be evaluated neurologically, placed on anticonvulsant therapy if not already instituted, and the dosage of ETAMEP re-examined to determine whether it should be decreased or the antibiotic discontinued. Dosage adjustment of ETAMEP is recommended in patients with reduced renal function (see **DOSAGE AND DIRECTIONS FOR USE**).

Applicant/PHCR: AUROBINDO PHARMA (PTY) LTD
Product proprietary name: ETAMEP
Dosage form and strength: LYOPHILISED POWDER FOR SOLUTION FOR INJECTION

As with other antibiotics, prolonged use of **ETAMEP** may result in overgrowth of non-susceptible organisms. Repeated evaluation of the patient's condition is essential. If superinfection occurs during therapy, appropriate measures should be taken.

There have been reports of Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome) after the use of **ETAMEP**.

ETAMEP is more stable to renal dehydropeptidase I than imipenem and use with cilastatin, which inhibits the enzyme, is not required.

ETAMEP should not be given to patients known to be hypersensitive to it, and should be given with caution to patients known to be hypersensitive to penicillins, cephalosporins, or other beta lactams because of the possibility of cross-sensitivity.

It should be given with caution to patients with renal impairment, and the dose reduced appropriately. Particular care is necessary in patients with CNS disorders such as epilepsy.

ETAMEP is not recommended in infants under 3 months of age as no data are available.

Effects on ability to drive and use machines

There is no data to suggest that **ETAMEP** affects the ability to drive and operate machinery. Due to the possibility of the side effects such as dizziness, seizures and altered mental status occurring, the patient should be advised not to drive or operate any heavy machinery until the effect of **ETAMEP** on the patient is known.

INTERACTIONS:

Probenecid inhibits the renal excretion of **ETAMEP** thereby increasing its plasma concentrations and prolonging its elimination half-life.

In vitro studies indicate that ertapenem does not inhibit P-glycoprotein-mediated transport of digoxin or vinblastine and that ertapenem is not a substrate for P-glycoprotein-mediated transport. *In vitro* studies in human liver microsomes indicate ertapenem does not inhibit metabolism mediated by any of the six major cytochrome P450 (CYP) isoforms: 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4. Drug interactions caused by inhibition of P-glycoprotein-mediated drug clearance or CYP-mediated drug clearance are unlikely (see **Pharmacokinetic properties**).

No specific clinical drug interaction studies have been conducted.

Applicant/PHCR: AUROBINDO PHARMA (PTY) LTD
Product proprietary name: ETAMEP
Dosage form and strength: LYOPHILISED POWDER FOR SOLUTION FOR INJECTION

Decreased serum levels of valproic acid with co-administration of ertapenem have been reported as post-marketing experiences. Careful monitoring of serum levels of valproic acid should be considered if ertapenem is to be co-administered with valproic acid.

PREGNANCY AND LACTATION:

Safety in pregnancy has not been established.

ETAMEP is excreted in human milk (see **Pharmacokinetic properties, Distribution**). Safety in nursing mothers has not been established.

DOSAGE AND DIRECTIONS FOR USE:

The usual dose of **ETAMEP** in patients 13 years of age and older is 1 gram (g) given once a day.

The usual dose of **ETAMEP** in patients 3 months to 12 years of age is 15 mg/kg twice daily (not to exceed 1g/day).

ETAMEP may be administered by intravenous (IV) infusion or intramuscular (IM) injection. When administered intravenously, **ETAMEP** should be infused over a period of 30 minutes.

Intramuscular administration of **ETAMEP** may be used as an alternative to intravenous administration in the treatment of those infections for which intramuscular therapy is appropriate.

The usual duration of therapy with **ETAMEP** is 3 to 14 days but varies by the type of infection and causative pathogen(s) (see **INDICATIONS**). When clinically indicated, a switch to an appropriate oral antimicrobial may be implemented if clinical improvement has been reported.

Dosage guidelines for adults and paediatric patients with normal renal function* and body weight			
Infection	Daily dose (IV or IM) Adults and paediatric patients 13 years of age and older	Daily dose (IV or IM) Paediatric patients 3 months to 12 years of age	Recommended duration of total antimicrobial treatment
Complicated intra-abdominal Infection	1 g	15 mg/kg twice daily [§]	5 to 14 days

Complicated skin and skin structure infections including diabetic lower extremity and diabetic foot infections	1 g	15 mg/kg twice daily [§]	7 to 14 days ^{†‡}
Community acquired pneumonia	1 g	15 mg/kg twice daily [§]	10 to 14 days [†]
Complicated urinary tract infections including pyelonephritis	1 g	15 mg/kg twice daily [§]	10 to 14 days [†]
Acute pelvic infections including postpartum endomyo-metritis, septic abortion and post-surgical gynaecologic infections	1 g	15 mg/kg twice daily [§]	3 to 10 days
<p>* Defined as creatinine clearance greater than 90 mL/min/1,73 m²</p> <p>[†] Duration includes a possible switch to an appropriate oral therapy once clinical improvement has been demonstrated.</p> <p>[§] Not to exceed 1 g per day</p> <p>[‡] Patients with diabetic foot infections received up to 28 days of treatment (parenteral or parenteral plus oral switch therapy)</p>			

In controlled clinical studies, patients were treated from 3 to 14 days. Total treatment duration was determined by the treating medical practitioner based on site and severity of the infection, and on the patient's clinical response. In some studies, treatment was converted to oral therapy at the discretion of the treating medical practitioner after clinical improvement had been demonstrated.

Patients with renal insufficiency

ETAMEP may be used for the treatment of infections in adult patients with renal insufficiency. In patients whose creatinine clearance is greater than 30 mL/min/1,73 m², no dosage adjustment is necessary. Adult patients with advanced renal insufficiency (creatinine clearance less than or equal to 30 mL/min/1,73 m²), including those on haemodialysis, should receive 500 mg daily. There are no data in paediatric patients with renal insufficiency.

Patients on haemodialysis

In a clinical study, following a single 1 g IV dose of **ETAMEP** given immediately prior to a haemodialysis session, approximately 30 % of the dose was recovered in the dialysate. When adult patients on haemodialysis are given the recommended daily dose or 500 mg of **ETAMEP** within 6 hours prior to haemodialysis, a supplementary dose of 150 mg is recommended following the haemodialysis session. If **ETAMEP** is given at least 6 hours prior to haemodialysis, no supplementary dose is needed. There are no data in patients undergoing peritoneal dialysis or hemofiltration. There is no data available for paediatric patients on haemodialysis.

When only the serum creatinine is available, the following formula** may be used to estimate creatinine clearance. The serum creatinine should represent a steady state of renal function.

$$\text{Males: } \frac{(\text{weight in kg}) \times (140 - \text{age in years})}{\text{serum creatinine } (\mu\text{mol/L})}$$

Females: (0,85) x (value calculated for males)

**Cockcroft and Gault equation: Cockcroft DW, Gault MH, Prediction of creatinine clearance from serum creatinine, Nephron. 1976

No dosage adjustment is recommended in patients with impaired hepatic function (see **Pharmacokinetic properties, Special population, Hepatic insufficiency**).

The recommended dose of **ETAMEP** can be administered without regard to age (13 years of age and older) or gender.

INSTRUCTIONS FOR USE

Patients 13 years of age and older

Preparation for intravenous administration:

DO NOT MIX OR CO-INFUSE **ETAMEP** WITH OTHER MEDICINES.

DO NOT USE DILUENTS CONTAINING DEXTROSE (α -D-GLUCOSE).

ETAMEP MUST BE RECONSTITUTED AND THEN DILUTED PRIOR TO ADMINISTRATION.

1. Reconstitute the contents of a 1 g vial of **ETAMEP** with 10 mL of one of the following: Water for Injection, 0,9 % Sodium Chloride Injection (154 mmol/L) or Bacteriostatic Water for Injection.
2. Shake well to dissolve and immediately transfer contents of the reconstituted vial to 50 mL of 0,9 % Sodium Chloride Injection (154 mmol/L).
3. Complete the infusion within 6 hours of reconstitution.

Preparation for intramuscular administration:

ETAMEP MUST BE RECONSTITUTED PRIOR TO ADMINISTRATION.

1. Reconstitute the contents of a 1 g vial of **ETAMEP** with 3,2 mL of 1,0 % or maximum 3,2 mL of 2,0 % lidocaine hydrochloride injection (**without epinephrine**). Shake vial thoroughly to form solution. This represents the maximum recommended dose of lidocaine.
2. Immediately withdraw the contents of the vial and administer by deep intramuscular injection into a large muscle mass (such as the gluteal muscles or lateral part of the thigh).
3. The reconstituted IM solution should be used within 1 hour after preparation.

Note: This reconstituted solution for intramuscular administration should not be administered intravenously.

Paediatric patients 3 months to 12 years of age

Preparation for intravenous administration:

DO NOT MIX OF CO-INFUSE **ETAMEP** WITH OTHER MEDICINES.

DO NOT USE DILUENTS CONTAINING DEXTROSE (α -D-GLUCOSE).

ETAMEP MUST BE RECONSTITUTED AND THEN DILUTED PRIOR TO ADMINISTRATION.

1. Reconstitute the contents of a 1 g vial of **ETAMEP** with 10 mL of one of the following: Water for Injection, 0,9 % Sodium Chloride Injection (154 mmol/L) or Bacteriostatic Water for Injection

Applicant/PHCR: AUROBINDO PHARMA (PTY) LTD
Product proprietary name: ETAMEP
Dosage form and strength: LYOPHILISED POWDER FOR SOLUTION FOR INJECTION

2. Shake well to dissolve and immediately withdraw a volume equal to 15 mg/kg of body weight (not to exceed 1 g/day) and dilute in 0,9 % Sodium Chloride Injection (154 mmol/L) to a final concentration of 20 mg/mL or less.
3. Complete the infusion within 6 hours of reconstitution.

Preparation for intramuscular administration:

ETAMEP MUST BE RECONSTITUTED PRIOR TO ADMINISTRATION.

1. Reconstitute the contents of a 1 g vial of **ETAMEP** with 3,2 mL of 1,0 % or maximum 3,2 mL of 2,0 % lidocaine hydrochloride injection (**without epinephrine**). Shake vial thoroughly to form solution. This represents the maximum recommended dose of lidocaine.
2. Immediately withdraw a volume equal to 15 mg/kg of body weight (not to exceed 1 g/day) and administer by deep intramuscular injection into a large muscle mass (such as the gluteal muscles or lateral part of the thigh).
3. The reconstituted IM solution should be used within 1 hour after preparation.

Note: This reconstituted solution for intramuscular administration should not be administered intravenously.

Parenteral pharmaceutical products should be inspected visually for particulate matter and discoloration prior to use, whenever solution and container permit. Solutions of **ETAMEP** range from colourless to pale yellow. Variations of colour within this range do not affect the potency of the product.

SIDE EFFECTS:

Immune system disorders:

Less frequent: Allergic reaction

Frequency unknown: Anaphylaxis including anaphylactoid reactions

Psychiatric disorders:

Frequent: Altered mental status

Nervous system disorders:

Frequent: Headache

Less frequent: Seizures, anxiety, dizziness, insomnia

Applicant/PHCR: AUROBINDO PHARMA (PTY) LTD
Product proprietary name: ETAMEP
Dosage form and strength: LYOPHILISED POWDER FOR SOLUTION FOR INJECTION

Frequency unknown: Hallucinations

Cardiac disorders:

Less frequent: Tachycardia

Vascular disorders:

Frequent: Infused vein complication

Less frequent: Phlebitis or thrombophlebitis, hypertension, hypotension

Respiratory, thoracic and mediastinal disorders:

Less frequent: Cough, dyspnoea or respiratory distress, pharyngitis

Gastrointestinal disorders:

Frequent: Diarrhoea, nausea

Less frequent: Pseudomembranous colitis, constipation, dyspepsia, oral candidiasis, vomiting, acid regurgitation

Skin and subcutaneous tissue disorders:

Less frequent: Erythema, pruritus, rash

Musculoskeletal, connective tissue and bone disorders:

Less frequent: Leg pain

Reproductive system and breast disorders:

Less frequent: Vaginitis

Investigations:

Frequent: Elevated ALT, AST, alkaline phosphatase, platelet count, decrease in neutrophil count.

Less frequent: Increase in direct serum bilirubin, total serum bilirubin, eosinophils, indirect serum bilirubin, PTT, urine bacteria, serum urea, serum creatinine, serum glucose, monocytes, urine epithelial cells, urine red blood cells, decreases in segmented neutrophils, white blood cells, haematocrit and haemoglobin.

General disorders and administrative site conditions:

Frequent: Chest pain, fever

Less frequent: Asthenia or fatigue, oedema

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:

Treatment

ETAMEP
(Ertapenem 1 g/Vial, Lyophilised Powder for Solution for Injection)

Applicant/PHCR: AUROBINDO PHARMA (PTY) LTD
Product proprietary name: ETAMEP
Dosage form and strength: LYOPHILISED POWDER FOR SOLUTION FOR INJECTION

In the event of an overdose, **ETAMEP** should be discontinued and general supportive treatment given until renal elimination takes place.

ETAMEP can be removed by haemodialysis; however, no information is available on the use of haemodialysis to treat overdosage.

IDENTIFICATION:

White to off white lyophilised cake or powder. When reconstituted, it is a clear colourless to pale yellow solution free from particles.

PRESENTATION:

20 mL clear transparent type-I glass tubular vial of 20 mm neck stoppered with 20 mm grey bromobutyl rubber stopper and sealed with 20 mm white aluminium PP disc.

Pack size: Printed cardboard carton containing 1 vial only.

STORAGE INSTRUCTIONS:

Lyophilised powder:

Store at or below 25 °C.

Reconstituted solutions:

IV use: The reconstituted solution, immediately diluted in 0,9 % of sodium chloride injection, may be stored at room temperature (25 °C) and used within 6 hours or stored for 24 hours under refrigeration (5 °C) and used within 4 hours after removal from refrigeration.

IM use: The reconstituted solution should be used within 1 hour after preparation.

Solutions of **ETAMEP** should not be frozen. Any unused portion of solutions of **ETAMEP** should be discarded.

STORE ALL VIALS OUT OF REACH OF CHILDREN.

REGISTRATION NUMBER:

51/20.1.1/0747

Applicant/PHCR: AUROBINDO PHARMA (PTY) LTD
Product proprietary name: ETAMEP
Dosage form and strength: LYOPHILISED POWDER FOR SOLUTION FOR INJECTION

HOLDER OF THE CERTIFICATE OF REGISTRATION:

Aurogen SA (Pty) Ltd

Woodhill Office Park, Building 1, First Floor

53 Phillip Engelbrecht Avenue

Meyersdal, Ext. 12, 1448

Johannesburg

South Africa

DATE OF PUBLICATION OF THIS PROFESSIONAL INFORMATION:

17 March 2020